Indication
Opioid Withdrawal
10 clinical trials
12 products
2 drugs
Product
DexmedetomidineProduct
PlaceboClinical trial
A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on OpioidsStatus: Completed, Estimated PCD: 2021-02-18
Clinical trial
A Phase 2, Open-Label, Randomized, Controlled, Ascending Dose Cohort, Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to OpioidsStatus: Recruiting, Estimated PCD: 2024-05-01
Product
Standard of CareClinical trial
Evaluating a Mechanistically-Supported Pharmacotherapy to Treat Opioid WithdrawalStatus: Recruiting, Estimated PCD: 2027-01-31
Product
BuspironeProduct
LofexidineClinical trial
Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD: A Pilot Double-blind, Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2025-02-01
Product
PramipexoleClinical trial
Evaluating a Neuromodulator Medical Device (Bridge Device) for Opioid Use Disorder TreatmentStatus: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
Assessing a Clinically-meaningful Opioid Withdrawal PhenotypeStatus: Recruiting, Estimated PCD: 2025-11-30
Product
MorphineProduct
Naloxone + LofexidineProduct
NaloxoneClinical trial
Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM): Can it Increase the Success of Transition to Naltrexone?Status: Completed, Estimated PCD: 2023-03-23
Product
PregabalinClinical trial
A Randomized Placebo-Controlled Evaluation of the Safety of Oral Cannabidiol in a Clinically Relevant Model of Opioid WithdrawalStatus: Completed, Estimated PCD: 2022-06-30
Drug
cannabidiolDrug
VarlilumabClinical trial
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine MicrodosingStatus: Recruiting, Estimated PCD: 2024-06-30
Product
Buprenorphine/naloxoneClinical trial
Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid WithdrawalStatus: Recruiting, Estimated PCD: 2025-01-30
Product
BXCL501